Angiotensin II receptors and renin release in rat glomerular afferent arterioles  by Chatziantoniou, Christos et al.
Kidney International, Vol. 46 (1994), pp. 1570—1573
Angiotensin II receptors and renin release in rat glomerular
afferent arterioles
CHRISTOS CRkTZIANT0NI0u, JEAN-CLAUDE DUSSAULE, WILLIAM J. ARENDSHORST,
and RAYMOND ARDAILLOU
INSER.M U.64, Tenon Hospita4 Paris, France, and Department of Physiology, University of North Carolina, Chapel Hi14 North Carolina, USA
Angiotensin H receptors and renin release in rat glomerular afferent
arterioles. The purpose of recent studies was to investigate the expression
of angiotensin II (Ang II) receptor sites in afferent arterioles freshly
isolated from the rat kidney, and the role of Ang II on renin release by
these vessels. The method of isolation and purification of renal microves-
sels was based on iron oxide infusion into the kidneys and separation of
the afferent arterioles from glomeruli and connective tissue with the aid of
a magnetic field, successive passages through various sieves, and harvest-
ing with collagenase. Ang II receptor characteristics were evaluated by
radioligand binding studies using the non-peptide Ang II antagonists of
AT1 (Dup-753 and -532) and AT2 (PD-123319 and CGP-42112) receptors.
AT1 antagonists displaced up to 80% of the Ang II binding with high
affinity (3 nM), whereas the remaining 20% showed low affinity for the Dup
compounds and CGP-42112 (>10 .tM), and intermediate affinity for
PD-123319 (12 gM), These data suggest the existence of two Ang II
receptor subtypes in the renal vasculature of the rat. In separate experi-
ments, renin release by isolated afferent arterioles in vitro was 9 ng/hr/mg
under control conditions. Ang 11(0.1 jiM) inhibited renin secretion by
20%, whereas the adenylyl cyclase activator forskolin (10 jiM) stimulated
renin secretion by 50%. In arterioles isolated from rats chronically treated
with a converting enzyme inhibitor (perindoprilate) to reduce endogenous
formation of Ang II, renin release increased 20-fold under control
conditions in vitro and was further stimulated by forskolin. These results
demonstrate that this preparation is a useful tool to study the functional
role of Mg II and the control of renin release in the afferent arterioles.
The renin-angiotensin system (RAS) plays a major role in the
renal function. Although several investigations attempted to
localize the exact sites of angiotensin II (Ang II) action on the
renal vasculature, controversy still remains on whether Ang II can
act on the preglomerular vessels [1]. Micropuncture and clearance
techniques and studies on microdissected vessels suggest that Ang
II constricts preferentially the efferent arteriole [2, 3] On the
other hand, data obtained from in vitro visualization models
(juxtaglomerular perfused nephron, hydronephrotic kidney) sup-
port the view that Ang II cnn act on afferent arterioles [4, 5].
Previous studies from our laboratories indirectly supported the
latter hypothesis. Ang II receptors have been identified on
isolated glomeruli and cultured mesangial cells, a structure that is
thought to share several common characteristics with preglomeru-
lar vascular smooth muscle cells [6, 7]. Furthermore, injection of
Ang II directly into the renal artery decreased renal blood flow by
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50 to 60% [8]. Renal vasoconstriction of this magnitude is difficult
to be achieved without participation of preglomerular vessels.
The purpose of the present study was to provide convincing
evidence demonstrating the existence of functional receptor sites
of Ang II in the preglomerular vasculature. For this reason we
developed a technique to isolate in vitro pure and viable prepa-
rations of preglomerular vessels from the rat kidney, and we
subsequently studied the regulation and expression of the renin-
angiotensin system in these vessels.
Methods
Isolation of afferent arterioles
The technique to isolate afferent arterioles from the rat kidney
was the same as previously described [9]. Briefly, a magnetized
iron oxide suspension (1% Fe3O4 in isotonic saline) was perfused
into the renal arteries of seven-week-old Wistar-Kyoto (receptor
binding studies) or Sprague Dawley (renin release studies) rats (6
rats per experiment) (Fig. 1A). Thereafter the kidneys were
removed, decapsulated, and the cortex was dissected from the
medulla. Cortical tissue was homogenized with a Polytron homog-
enizer, and the iron oxide-loaded tissues (renal vessels and
glomeruli) were removed from the crude homogenate with the aid
of a magnet (Fig. 1B). Afferent arterioles were separated from
larger vessels and glomeruli using repetitive passages through
needles and sieves of decreasing sizes (20 to 23 gauge and 150 to
90 jxm, respectively). The microvessels were recovered from the
top of the 125 jim sieve and harvested with collagenase (55 U/mI)
for 30 minutes at 37°C to remove the surrounding connective
tissue. Only vascular preparations containing >90% of afferent
arterioles were retained for subsequent experiments.
Receptor binding studies
Aliquots of microvessels (40 j.tg of protein) were incubated with
increasing concentrations of 3H-Ang II as previously described
[9]. Nonspecific binding was determined in the presence of an
excess of unlabeled Ang 11(10 jim). In competitive inhibition
studies, the AT1 receptor antagonists Dup-753 and Dup-532
(DuPont) and the AT2 receptor antagonists PD-123319 (Parke-
Davis) and CGP-42112 (Ciba-Geigy) were used to displace 3H-
Mg II. Analyses of the data using the LIGAND program gave
estimates of the maximum specific binding (Bmj and dissocation
constant (Kd).
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Renin release evaluation
Aliquots of microvessels (150 to 200 tg of protein) were
incubated at 37°C in a final volume of 1 ml DMEM/F12 (1:1)
medium containing 1 mcvi Ca2. Incubations lasted one and three
hours in the absence or presence of 10 .tM of forskolin or 0.1 iM
of Ang II. Renin release was measured by radioimmunoassay as
the amount of Ang I produced by incubation of supernatants with
an excess of rat renin substrate (plasma of binephrectomized rats)
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Renin release was expressed in nanograms of Ang I gener-
ated per hour of incubation per milligram of protein of afferent
arterioles.
Angiotensin converting enzyme (ACE) inhibition
In separate experiments, rats were treated with a converting-
enzyme inhibitor (perindoprilate, 40 mg/kg/day) for five days to
eliminate endogenous Ang II. Isolation of afferent arterioles and
renin release assay were performed as described above.
Results
Receptor binding studies
The properties of Ang II receptor sites were characterized in
afferent arterioles from seven-week-old rats using equilibrium
radiolabeled techniques. Scatchard analysis revealed one class of
high affinity receptors (Kd = 1 flM) with a density of 200 fmollmg
of protein.
To identif' the Ang II subtype(s) expressed in these renal
vessels, the AT1 antagonists Dup-753 and Dup-532, and the AT2
antagonists PD-123319 and CGP-42112 were used to displace
unlabeled Ang II. The AT1 antagonists displaced almost com-
pletely the Ang II binding. Analysis of the displacement curve by
the LIGAND program indicated that a two-site model produced
a significantly better fit than the one-site model (P < 0.00 1). In the
two-site model, Dup-753 binds to one site with high affinity (3 nM),
whereas it displays 500-fold lower affinity for the other site (1.5
tkM; (Fig. 2A). The high-affinity site is the most abundant and
occupies 80% of the total Ang II receptor sites. The low-affinity
Ang II site occupies the remaining 20% of the total receptor sites.
The putative AT2 antagonist PD-123319 displaced up to 25% of
the Ang II binding, with a rather medium affinity (100 nM; Fig.
2B). The other AT2 antagonist, CGP-42112, showed very low
affinity to the Ang II receptor sites (> 10 tM).
To determine whether or not the high affinity site that Dup-753
bound to is distinct from the medium affinity site recognized by
PD-123319, competitive inhibition curves were performed by
adding a standard concentration of PD-123319 (1 jiM) to increas-
ing concentrations of Dup-753, and alternatively, by adding a
standard concentration of Dup-753 (10 nM) to increasing concen-
trations of PD-123319. As shown in Figure 2A, PD-123319
provided an additive displacement (15 to 20%) that was uniform
in all tested concentrations of Dup-753. Similarly, Dup-753 dis-
placed an additional 20 to 25% of the sites in all PD-123319 tested
concentrations (Fig. 2B).
Renin release studies
The viability of the afferent arterioles was checked by measure-
ments of creatine kinase activity (CKA) in the medium. No
changes in the release of CKA were observed between 0 and 6
hours after isolation of the vessels. On the contrary, CKA was
increased eightfold at 24 hours compared to 0 hours. For this
reason, renin release measurements were performed at 1 and 3
hours after isolation of afferent arterioles. During this period, the
rate of secretion of renin was increased significantly with time.
After 1 hour renin release in supernatants was 10 2 ng/hr/mg,
and after 3 hours it was 22 2 ng/hr/mg (Table 1).
To investigate whether renin release can be regulated in our
vascular preparation in vitro, we used forskolin and Ang II, two
agents that are known to stimulate and inhibit renin release,
Normal Perindoprilate
lhr 3hr lhr 3hr
Control 10 2 22 2 153 16 242 19
Forskolin 15 2 34 4 217 16 394 42
Ang II 8 1 15 2 125 10 160 14
Values are expressed in nglhr/mg and are means SE of 4 independent
experiments.
P < 0.05 vs. control
respectively. Addition of forskoljn (10 jiM) increased renin release
by 40% after 1 hour and 50% after 3 hours compared to control
values. In contrast, when exogenous Ang 11(0.1 jiM)was added,
renin release by afferent arterioles was decreased by 35% at 3
hours (Table 1).
To examine if in vivo regulation of the expression of the
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Fig. 2. Displacement curves of 3H-Ang II binding to preglomerular vessels
by increasing concentrations of the AT2 antagonist Dup 753 in absence and
presence of the AT2 antagonist PD 123319 (1 jiM) (A) and inversely, by
increasing concentrations of PD 123319 in absence and presence of Dup 753
(10 nM) (B). Values are means SE for 4 experiments of each condition.
Table 1. Renin release from afferent arterioles freshly isolated from
normal and perindoprilate-treated rats
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renin-angiotensin system can induce changes in renin release that
can be detected in isolated afferent arterioles, a group of rats was
treated chronically with a converting enzyme inhibitor (perindo-
prilate) to reduce production of endogenous Ang IL Afferent
arterioles from rats treated with perindoprilate were found to
release renin at a rate 15-fold higher than control. Addition of
forskolin further increased renin release (50 and 70% above
control at 1 and 3 hr, respectively), whereas addition of exogenous
Ang II inhibited renin release (30% below control at 3 hr).
Discussion
In the present studies, we isolated afferent arterioles of high
purity, and in sufficient quantity to perform several biochemical
studies such as receptor characterization or responses to a variety
of stimuli. This vascular preparation is viable in vitro, and it was
used to study Ang II receptor sites in biochemical (binding
characteristics) and functional (renin release regulation) terms.
The use of nonpeptide antagonists of Ang II indicated the
existence of two subtypes of Ang II receptors in the afferent
arterioles of rats. One site appears to be a typical vascular AT1
subtype since it displays high affinity to the AT1 antagonists
Dup-753 and Dup-532 and very low affinity to the AT2 antagonists
PD-123319 and CGP-42112. This subtype is predominant and
occupies 80% of the total number of Ang II receptor sites. The
other receptor subtype displays intermediate affinity to the AT2
antagonist PD-123319 and low affinity to AT1 antagonists. How-
ever, it does not appear to be the AT2 subtype found in the
adrenal gland, because it shows low affinity to CGP-421 12. Several
recent studies using molecular biology techniques indicated the
expression of two AT1 subtypes (designated as ATia and AT1b) in
the rat renal kidney [11, 121. Of particular interest, use of
quantitative PCR suggested that the relative ratio of the AT1,,
versus ATIb subtype in the renal cortex was 4:1 [12].
The characterization of Ang II receptor sites in freshly isolated
afferent arterioles does not necessarily mean that these sites are
functional. To verify the adequacy of this vascular preparation for
functional studies, we investigated the responsiveness of the
afferent arterioles to agents that control the expression of the
renin-angiotensin system, such as Ang II and forskolin. In control
rats, renin release was increased with time, it was inhibited by
exogenous Ang II, and it was stimulated by forskolin. It would be
interesting to investigate whether the two Ang II receptor sub-
types found in our preparation influence renin release differently.
In rats chronically treated with an ACE inhibitor, baseline renin
release was increased 15-fold. Such a large increase in renin
release is in agreement with studies indicating that in response to
ACE inhibition vascular smooth muscle cells of the renal vascu-
lature from afferent arteriole up to interlobar and arcuate arteries
express and release renin to a rate several times higher than the
normal [131. Interestingly, in the perindoprilate-treated rats,
isolated afferent arterioles continued to be responsive to exoge-
nous stimuli since renin release was increased or decreased
following exposure to forskolin or Ang II, respectively (Table 1).
In conclusion, we have described a reproducible technique to
isolate from the rat kidney afferent arterioles of high purity and in
sufficient quantities to perform biochemical studies such as Ang II
receptor characterization and regulation. The metabolic respon-
siveness of our vascular preparation to mediators of Ang II
receptor expression and renin release suggests that this model is a
useful tool to study the autocrine and paracrine regulation of the
renin-angiotensin system at the cellular level.
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